Angiodynamics (ANGO) Cash from Financing Activities (2010 - 2026)

Angiodynamics has reported Cash from Financing Activities for 17 years, with the latest figure at $621000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 91.31% year-over-year to $621000.0; the trailing twelve-month figure through Feb 2026 stood at -$5.1 million (down 1089.9% YoY), and the FY2025 full-year result was -$255000.0, up 99.6% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $621000.0, up from -$92000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $24.4 million in Q3 2022, with the low at -$59.6 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged -$2.3 million across 5 years, with a median of $123000.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 441.75% — and 2025, when it surged 929.83%.
• Angiodynamics' Cash from Financing Activities stood at $103000.0 in 2022, then tumbled by 441.75% to -$352000.0 in 2023, then sank by 219.03% to -$1.1 million in 2024, then surged by 91.81% to -$92000.0 in 2025, then jumped by 775.0% to $621000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $621000.0 (Q1 2026), -$92000.0 (Q4 2025), and $143000.0 (Q3 2025), per Business Quant data.